PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26614570-5 2016 We also examined whether such an effect is improved by sildenafil, an inhibitor of phosphodiesterase-5 which potentiates NO-induced increases in cyclic GMP. Sildenafil Citrate 55-65 5'-nucleotidase, cytosolic II Homo sapiens 152-155 27466020-2 2016 Sildenafil is a potent and selective phosphodiesterase-5 (PDE-5) inhibitor, which induces cyclic GMP accumulation. Sildenafil Citrate 0-10 5'-nucleotidase, cytosolic II Homo sapiens 97-100 21537000-7 2011 Antenatal sildenafil administered to the pregnant rat from embryonic day 11.5 to embryonic day 20.5 crossed the placenta, increased fetal lung cyclic GMP and decreased active PDE5 expression. Sildenafil Citrate 10-20 5'-nucleotidase, cytosolic II Homo sapiens 150-153 21193396-0 2011 Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. Sildenafil Citrate 114-124 5'-nucleotidase, cytosolic II Homo sapiens 41-44 21193396-0 2011 Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. Sildenafil Citrate 114-124 5'-nucleotidase, cytosolic II Homo sapiens 61-64 21193396-0 2011 Distinct allostery induced in the cyclic GMP-binding, cyclic GMP-specific phosphodiesterase (PDE5) by cyclic GMP, sildenafil, and metal ions. Sildenafil Citrate 114-124 5'-nucleotidase, cytosolic II Homo sapiens 61-64 19961855-1 2010 Increased cyclic GMP from enhanced synthesis or suppressed catabolism (e.g. PDE5 inhibition by sildenafil, SIL) activates protein kinase G (PKG) and blunts cardiac pathological hypertrophy. Sildenafil Citrate 95-105 5'-nucleotidase, cytosolic II Homo sapiens 17-20 20079349-9 2010 Our results indicate that glyceryl trinitrate and sildenafil reduce tactile allodynia in diabetic rats suggesting that nitric oxide and cyclic GMP supply is an important step in their mechanism of action of these drugs in diabetic animals. Sildenafil Citrate 50-60 5'-nucleotidase, cytosolic II Homo sapiens 143-146 20079349-10 2010 Data suggest that nitric oxide donors (as glyceryl trinitrate) and drugs which increase cyclic GMP levels (as sildenafil) could have a role in the pharmacotherapy of tactile allodynia in diabetic patients. Sildenafil Citrate 110-120 5'-nucleotidase, cytosolic II Homo sapiens 95-98 17179022-2 2007 Sildenafil, a type 5 phosphodiesterase inhibitor, lowers pulmonary vascular resistance in pulmonary hypertension by augmenting intracellular levels of the nitric oxide second messenger, cyclic GMP. Sildenafil Citrate 0-10 5'-nucleotidase, cytosolic II Homo sapiens 193-196 11137852-2 2001 To date, the most widely used phosphodiesterase 5 inhibitors, zaprinast and sildenafil, have proved vital in the elucidation of the widespread role of cyclic GMP in nitrergic transmission and, specifically in the case of sildenafil, have provided a major breakthrough in the treatment of erectile dysfunction in men. Sildenafil Citrate 76-86 5'-nucleotidase, cytosolic II Homo sapiens 158-161 16815627-4 2006 RESULTS: The promising clinical data for the orally active phosphodiesterase (PDE) inhibitors sildenafil, vardenafil and tadalafil, used in the treatment of male erectile dysfunction (MED), has boosted research activities on the significance of the cyclic GMP- and cyclic AMP pathway in other genitourinary tract tissues, such as the bladder, prostate, ureter, urethra, as well as female genital tissues. Sildenafil Citrate 94-104 5'-nucleotidase, cytosolic II Homo sapiens 256-259 16192518-9 2005 The plasma cyclic GMP concentrations were larger (P = 0.004) at LVC in the sildenafil group compared with placebo. Sildenafil Citrate 75-85 5'-nucleotidase, cytosolic II Homo sapiens 18-21 16380114-0 2006 Relaxation and cyclic GMP levels in response to sildenafil in human pulmonary arteries from donors. Sildenafil Citrate 48-58 5'-nucleotidase, cytosolic II Homo sapiens 22-25 16380114-4 2006 SNP (10(-7) M) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10(-6) M). Sildenafil Citrate 77-87 5'-nucleotidase, cytosolic II Homo sapiens 42-45 16380114-5 2006 Thus, the enhancement of SNP-induced relaxation by sildenafil is mainly due to an increase in cyclic GMP accumulation. Sildenafil Citrate 51-61 5'-nucleotidase, cytosolic II Homo sapiens 101-104 10210955-11 1999 Erection is dependent on elevated levels of cyclic GMP and sildenafil mediates its effects by inhibiting the degradation of cyclic GMP. Sildenafil Citrate 59-69 5'-nucleotidase, cytosolic II Homo sapiens 131-134 11053205-1 2000 Sildenafil (0.1 - 30 microM), a cyclic GMP phosphodiesterase 5 (PDE 5) inhibitor, induced inhibition of electrically evoked contractions of ring segments of human vas deferens from 34 vasectomies. Sildenafil Citrate 0-10 5'-nucleotidase, cytosolic II Homo sapiens 39-42 11053205-5 2000 SNP (10 microM) caused elevation of cyclic GMP levels that was potentiated by sildenafil (10 microM) and zaprinast (100 microM). Sildenafil Citrate 78-88 5'-nucleotidase, cytosolic II Homo sapiens 43-46 9658982-9 1998 Orally administered Sildenafil competitively inhibits phosphodiesterase type 5, which physiologically inactivates cyclic GMP in the erectile bodies. Sildenafil Citrate 20-30 5'-nucleotidase, cytosolic II Homo sapiens 121-124 9658982-10 1998 Thus, Sildenafil increases in men with erectile dysfunction the NO-stimulated cyclic GMP concentration and, thereby, improves erection. Sildenafil Citrate 6-16 5'-nucleotidase, cytosolic II Homo sapiens 85-88